China / Fosun Pharma in Profile
At a time when the country’s economy has fallen into a slump with the currency sinking to its lowest level in 16 years, Chinese giant Fosun Pharma continues to agressively…
Writing in the September 2023 edition of DIA’s Global Forum magazine, Shuting Li of Anhui Jimin Cancer Hospital and Xinfang Fan of Bayer Health Care Ltd. examine how Chinese clinical trials are increasingly focusing on patient engagement and patient centricity.…
At a time when the country’s economy has fallen into a slump with the currency sinking to its lowest level in 16 years, Chinese giant Fosun Pharma continues to agressively…
A roundup of some of the most significant recent stories from the Chinese pharmaceutical industry, including a slate of international investment which seems to suggest that – despite ongoing political…
The latest healthcare and life sciences news from China, including Eisai’s USD 2 billion oncology deal with Bliss Biopharma; Hasten Biopharmaceutic acquisition of commercial rights in China for Rocephin from…
Albert Wong of the Hong Kong Science and Technology Parks Corporation (HKSTP) outlines how Hong Kong has developed as an innovation hub, building on its established areas of finance and…
Novartis, one of the world’s largest biopharma companies, has secured approval and market access for two of its most advanced cell and gene treatments in Hong Kong. The firm’s territory…
Established in 2017 as a spin-off from Lee’s Pharmaceutical, Zhaoke Ophthalmology is aiming to be a global player in the ophthalmology field, building on its strong footprint in China and…
China has made major healthcare strides over the past decade with regulatory reforms, infrastructure improvements, and the advancement of universal healthcare. While the COVID-19 pandemic revealed the need for further…
Ongoing geopolitical tensions between China and the West have led the G7 group of countries to warn of the threat of “economic coercion” from China and the US to scrutinise…
A roundup of some of the latest healthcare and pharma news from China including a crackdown on healthcare corruption; AstraZeneca’s cardiovascular mortality drug approval and mRNA manufacturing deal with CanSino;…
A roundup of some of the biggest recent stories coming out of China, including the commerce minister’s peace offering to international drug companies; CSPC Pharmaceutical Group’s partnership with Pfizer; Merck’s…
Writing in the August edition of DIA’s Global Forum magazine, Wen Yin of the Pfizer China R&D Center and Wanhe Deng of GSK China Investment look back on four years…
Bridge Consulting examines the opportunities and challenges ahead for China’s mRNA vaccine industry in the post-COVID era. Having eschewed foreign-made mRNA products from Pfizer/BioNTech and Moderna during the peak of…
See our Cookie Privacy Policy Here